During the Congress of the European Society of Cardiology (ESC), Daiichi Sankyo presented new relevant data in the management of LDL cholesterol. The results show clinically relevant reductions in low-density lipoprotein cholesterol (LLD) in the first year of treatment, which are estimated to result in a significant reduction in cardiovascular risk to 10 years.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
During the Congress of the European Society of Cardiology (ESC), Daiichi Sankyo presented new relevant data in the management of LDL cholesterol. The results show clinically relevant reductions in low-density lipoprotein cholesterol (LLD) in the first year of treatment, which are estimated to result in a significant reduction in cardiovascular risk to 10 years.